eicosapentaenoic acid ethyl ester has been researched along with etc-1002 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al Rifai, M; Al-Mallah, MH; Jia, X; Martin, SS; Miedema, MD; Virani, SS | 1 |
| Lloyd-Jones, DM; Wilkins, JT | 1 |
1 review(s) available for eicosapentaenoic acid ethyl ester and etc-1002
| Article | Year |
|---|---|
Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dicarboxylic Acids; Eicosapentaenoic Acid; Fatty Acids; Female; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; United States | 2019 |
1 other study(ies) available for eicosapentaenoic acid ethyl ester and etc-1002
| Article | Year |
|---|---|
Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk.
Topics: Cardiovascular Diseases; Dicarboxylic Acids; Eicosapentaenoic Acid; Ezetimibe; Fatty Acids; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PCSK9 Inhibitors; RNA, Small Interfering | 2021 |